Bristol-Myers Squibb Company (BMY)vsIntel Corporation (INTC)
BMY
Bristol-Myers Squibb Company
$58.94
+2.70%
HEALTHCARE · Cap: $120.03B
INTC
Intel Corporation
$47.18
+7.08%
TECHNOLOGY · Cap: $220.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Intel Corporation generates 10% more annual revenue ($52.85B vs $48.19B). BMY leads profitability with a 14.6% profit margin vs -0.5%. INTC appears more attractively valued with a PEG of 0.50. BMY earns a higher WallStSmart Score of 64/100 (C+).
BMY
Buy64
out of 100
Grade: C+
INTC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.0%
Fair Value
$161.93
Current Price
$58.94
$102.99 discount
Intrinsic value data unavailable for INTC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 40 in profit
Large-cap with strong market position
Attractively priced relative to earnings
Strong operational efficiency at 28.2%
Generating 1.6B in free cash flow
Mega-cap, among the largest globally
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
1.3% revenue growth
Distress zone — elevated risk
Elevated debt levels
Distress zone — elevated risk
ROE of 0.0% — below average capital efficiency
Revenue declined 4.1%
Earnings declined 71.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Market Cap, P/E Ratio.
Bull Case : INTC
The strongest argument for INTC centers on Market Cap, PEG Ratio, Price/Book. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : BMY
The primary concerns for BMY are PEG Ratio, Revenue Growth, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : INTC
The primary concerns for INTC are Altman Z-Score, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
BMY profiles as a value stock while INTC is a turnaround play — different risk/reward profiles.
INTC carries more volatility with a beta of 1.38 — expect wider price swings.
BMY is growing revenue faster at 1.3% — sustainability is the question.
BMY generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
BMY scores higher overall (64/100 vs 42/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →Intel Corporation
TECHNOLOGY · SEMICONDUCTORS · USA
Intel Corporation is an American multinational corporation and technology company headquartered in Santa Clara, California, in Silicon Valley. It is the world's largest semiconductor chip manufacturer by revenue, and is the developer of the x86 series of microprocessors, the processors found in most personal computers (PCs).
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?